Life | Page 115 of 133 | SpiritIndia.com

Cancer :: Berkeley cancer genome center to study tumor genomics

The newly established Berkeley Cancer Genome Center, led by members of the Life Sciences Division in the Department of Energy’s Lawrence Berkeley National Laboratory, is one of seven Cancer Genome Characterization Centers to receive awards from the National Cancer Institute and the National Human Genome Research Institute. Earlier today the two institutes, both part of the National Institutes of Health, announced a three-year, $35 million project which will seek to identify important genetic changes involved in lung, brain, and ovarian cancers through genome analysis.

Pilates :: Top Six Benefits of Pilates Exercises

Pilates is the exercise of choice for dancers, gymnasts, and a host of famous Hollywood celebrities, and now it finds itself firmly entrenched in the mainstream. So why is pilates so hot? Pilates incredible popularity can be traced to the fact that it provides its faithful practitioners with benefits that you simply can’t get through traditional aerobics/strength training format.

Diabetes :: Top 5 Diabetes Diet Tips for Creating Healthy Meal Plan

Diet plays a key role in controlling your blood sugar. A healthy-eating plan tailored to your needs will do that and more. Majority of people affected with diabetes are overweight or obese. In fact, your risk of getting diabetes increases the more weight you put on.

Diabetes :: Plan Will Guide NIH Research in Type 1 Diabetes

The National Institutes of Health (NIH) has released a long range plan that will help to guide research in type 1 diabetes for the next decade. Advances and Emerging Opportunities in Type 1 Diabetes Research: A Strategic Plan identifies goals and objectives to exploit recent scientific advances in combating this autoimmune form of diabetes.

Allergy :: Experimental Ragweed Therapy Offers Allergy Sufferers Longer Relief with Fewer Shots

Americans accustomed to the seasonal misery of sneezing, runny noses and itchy, watery eyes caused by ragweed pollen might one day benefit from an experimental allergy treatment that not only requires fewer injections than standard immunotherapy, but leads to a marked reduction in symptoms that persists for at least a year after therapy has stopped, according to a new study in the October 5 issue of The New England Journal of Medicine (NEJM). The research was sponsored by the Immune Tolerance Network, which is funded by the National Institute of Allergy and Infectious Diseases (NIAID) and the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), both components of the National Institutes of Health (NIH), and the Juvenile Diabetes Research Foundation International.

Schizophrenia :: Solvay pharmaceuticals and Wyeth – new drug for bifeprunox to treat schizophrenia

Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), announced today that a New Drug Application (NDA) was submitted to the U.S. Food and Drug Administration (FDA) for bifeprunox, an investigational atypical antipsychotic for the treatment of schizophrenia.

Smoking :: Nabi biopharmaceuticals completes enrollment in nicvax phase iib ‘proof-of-concept’ clinical trial

Nabi Biopharmaceuticals (Nasdaq: NABI) today announced it has completed enrollment for its Phase IIB “proof-of-concept” study for NicVAX(R) (Nicotine Conjugate Vaccine), the company’s novel, innovative and proprietary investigational vaccine being developed to treat nicotine addiction and prevent smoking relapse. Enrollment for the trial was completed three months earlier than anticipated, paving the way for the release of trial results early in the second quarter of 2007.

Obesity :: Manhattan pharmaceuticals – oral oleoyl-estrone clinical program to include morbidly obese

Manhattan Pharmaceuticals, Inc. (Amex: MHA) today announced expansion of its oral Oleoyl-estrone (OE) clinical obesity program to include the morbidly obese. A new US Phase 2a clinical trial evaluating oral OE in morbidly obese male subjects will be initiated in October 2006. The morbidly obese population in the US is estimated to be 14 million people. OE is the Company’s orally administered product candidate in development for the treatment of obesity.

Cancer :: Agencourt genomic services is key collaborator in new study on breast and colon cancer genes

Agencourt Bioscience Corporation, a Beckman Coulter company, has announced that its Genomic Services were integral in a breakthrough Johns Hopkins study on the genetic code for breast and colon cancers. A recent and widely publicized report on that study, published this month in Science Express, was co-authored by James Hartigan, an Agencourt project manager. The research identifies close to 200 mutated genes, now linked to these cancers, most of which were not previously recognized as associated with tumor initiation, growth, spread or control. The study provides an understanding into disease processes and is expected to drive cancer research for years to come.

Gene :: Does missing gene point to nocturnal existence for early mammals?

A gene that makes cells in the eye receptive to light is missing in humans, researchers have discovered. They say that whereas some animals like birds, fish and amphibians have two versions of this photoreceptor, mammals, including humans, only have one. The findings – published in the Public Library of Science journal PLoS Biology – reveal how our experience of the light environment may be impoverished compared to other vertebrates and fits with the suggestion that early mammals were at one time wholly nocturnal creatures.